Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled trial of elafibranor in adults with primary biliary cholangitis and cirrhosis
MOH_2025-06-25_014161Phase 3Not yet recruiting
- Sponsor
- Ipsen
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary biliary cholangitis (PBC) comparing Elafibranor daily with Placebo daily (2 arms). Primary endpoint: Clinical worsening events. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
elafibranor
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on MOH_2025-06-25_014161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-06-25_014161.